In a Phase 1 trial, women responded well to the novel vaccine. More research is needed to determine whether it can stop the cancer from recurring or possibly prevent it entirely.

Jennifer Davis is the first person to receive the breast cancer vaccine as part of a clinical trial. (Photo illustration: Yahoo News; photos: Getty Images) Finding a cure for cancer has been the holy ...

ST. LOUIS – A groundbreaking treatment has been announced for women with an extremely aggressive form of breast cancer. Siteman Cancer Center just released the results of a clinical trial showing a ...

Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...

Patient-derived xenografts (PDX) may accurately predict early recurrence and survival outcomes in triple negative breast cancer (TNBC), offering a potential tool for tailoring treatment strategies to ...

According to a Cleveland Clinic-issued statement, researchers with the institution have announced the final results of a ...

Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.

Improved 3-year disease-free and recurrence-free survival seen with intensive chemotherapy regimen. HealthDay News — For patients with operative triple-negative breast cancer, a multigene signature ...

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

KEYTRUDA in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and human ...

Finding a cure for cancer has been the holy grail in medicine for years. With the exception of the only two cancer vaccines currently available — one for HPV, strains of which can cause cancer, ...